<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297865</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_JSI_101</org_study_id>
    <nct_id>NCT04297865</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      CJ-15314 phosphate in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To evaluate the safety, tolerability and pharmacokinetics of single or multiple dose of&#xD;
           CJ-15314 phosphate in healthy male subjects&#xD;
&#xD;
        -  To explore the pharmacodynamics of single or multiple dose of CJ-15314 phosphate in&#xD;
           healthy male subjects&#xD;
&#xD;
        -  To explore the pharmacokinetics of CJ-15314 Phosphate active metabolites of single or&#xD;
           multiple dose of CJ-15314 phosphate in healthy male subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PTF of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ra of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ra of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of A as CJ-15314 or placebo once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of B as CJ-15314 or placebo once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of C as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of D as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of E as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of F as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A dose as CJ-15314</intervention_name>
    <description>A dose as CJ-15314, 1 capsule</description>
    <arm_group_label>A dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B dose as CJ-15314</intervention_name>
    <description>B dose as CJ-15314, 1 capsule</description>
    <arm_group_label>B dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C dose as CJ-15314</intervention_name>
    <description>C dose as CJ-15314, 1 capsule</description>
    <arm_group_label>C dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D dose as CJ-15314</intervention_name>
    <description>D dose as CJ-15314, 2 capsules</description>
    <arm_group_label>D dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E dose as CJ-15314</intervention_name>
    <description>E dose as CJ-15314, 1 capsule</description>
    <arm_group_label>E dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F dose as CJ-15314</intervention_name>
    <description>F dose as CJ-15314, 2 capsules</description>
    <arm_group_label>F dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>A dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>B dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>C dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 capsules</description>
    <arm_group_label>D dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>E dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 capsules</description>
    <arm_group_label>F dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male adults aged 19 to 55 years (inclusive) at the time of signing the&#xD;
             informed consent form.&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m^2 with a body weight ≥ 50.0 kg and ≤ 90.0&#xD;
             kg at screening.&#xD;
&#xD;
             ☞ BMI (kg/m^2) = weight (kg) / {height (m)}^2&#xD;
&#xD;
          -  Decides to participate voluntarily in the study after being fully informed of and&#xD;
             understanding the study completely, and provides his written informed consent prior to&#xD;
             screening procedure.&#xD;
&#xD;
          -  Determined eligible for this study in the opinion of the investigator based on the&#xD;
             results of vital signs, physical examination, 12-lead electrocardiogram, clinical&#xD;
             laboratory tests, and medical interview drug screening test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history or current evidence of clinically significant disorder of hepatic,&#xD;
             renal, nervous, respiratory, endocrine, hemato-oncologic, cardiovascular, urinary,&#xD;
             and/or psychiatric system.&#xD;
&#xD;
          -  Has a history or current evidence of gastrointestinal disease that may affect the&#xD;
             safety and PD assessment of IP or a history of gastrointestinal surgery (except for&#xD;
             simple appendectomy or herniotomy).&#xD;
&#xD;
          -  Has rheumatoid arthritis or has a history.&#xD;
&#xD;
          -  Has symptomatic herpes simplex or herpes zoster or has a history within 3 months prior&#xD;
             to the scheduled first dose.&#xD;
&#xD;
          -  Has live vaccine dose within 3 months prior to the scheduled first dose or expects to&#xD;
             receive live vaccine during the clinical trial period.&#xD;
&#xD;
          -  Has a history or current evidence of clinically significant hypersensitivity to drugs&#xD;
             containing any ingredient of Janus kinase inhibitor and other drugs.&#xD;
&#xD;
          -  Has a positive result on serology tests (for hepatitis B, hepatitis C and human&#xD;
             immunodeficiency virus [HIV]) during screening test.&#xD;
&#xD;
          -  Has abnormalities one or more of the following during screening test: AST [GOT] or ALT&#xD;
             [GPT] &gt; 1.5 X upper limit of normal (ULN), Creatinine &gt; upper limit of normal (ULN),&#xD;
             ANC &lt; 2,000/uL, Hb &lt;12.5 g/dL, Platelet &lt; 150,000/uL, QTc interval at 12-lead&#xD;
             electrocardiogram &gt; 450 msec&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &lt; 90 mmHg or &gt; 140 mmHg, diastolic blood pressure (DBP)&#xD;
             &lt; 50 mmHg or &gt; 95 mm Hg, or pulse rate (PR) &lt; 45 beats/min or &gt; 100 beats/min on vital&#xD;
             signs measured in sitting position after taking a rest for at least 5 minutes during&#xD;
             screening test.&#xD;
&#xD;
          -  Has a history of drug abuse or has a positive response to drug abuse on urine drug&#xD;
             screening test.&#xD;
&#xD;
          -  Has taken any prescription drugs or herbal medicine within 2 weeks prior to the&#xD;
             expected date of first dose, or has taken or is expected to take any over-the-counter&#xD;
             (OTC) drug, health functional food or vitamin preparation within 1 week prior to the&#xD;
             expected date of the first dose (However, can participate in the study if otherwise&#xD;
             eligible in the judgment of the investigator).&#xD;
&#xD;
          -  Has participated in any other clinical study or bioequivalence study and received IPs&#xD;
             within 6 months prior to the scheduled first dose.&#xD;
&#xD;
          -  Has donated whole blood within 2 months prior to the scheduled first dose, or has&#xD;
             donated blood components or received transfusion within a month prior to the scheduled&#xD;
             first dose.&#xD;
&#xD;
          -  Has a history of excessive smoking (&gt; 10 cigarettes/day) within 3 months prior to the&#xD;
             scheduled first dose or confirmed as positive for cotinine on urine drug screening&#xD;
             test.&#xD;
&#xD;
          -  Excessive caffeine intake (&gt; 5 units/day), continued use of alcohol (&gt; 21 units/week,&#xD;
             1 unit = 10 g of pure alcohol), or unable to stop drinking during hospitalization&#xD;
             period.&#xD;
&#xD;
          -  Unable to avoid caffeine-containing foods (e.g., coffee, tea [black tea, green tea,&#xD;
             etc.], soda, coffee-flavored milk, and nutritive tonic drink) during the period from&#xD;
             24 hrs before hospitalization to discharge.&#xD;
&#xD;
          -  Unable to use a medically acceptable contraceptive method throughout the study.&#xD;
&#xD;
             ► Medically acceptable contraceptive methods include:&#xD;
&#xD;
               1. Use of intrauterine device with a proven birth control failure rate by the spouse&#xD;
                  (or partner)&#xD;
&#xD;
               2. Simultaneous use of (male or female) barrier method and spermicide&#xD;
&#xD;
               3. Surgical sterilization of the subject or his partner (e.g., vasectomy,&#xD;
                  salpingectomy, tubal ligation, or hysterectomy)&#xD;
&#xD;
          -  Determined ineligible for study participation by the investigator for other reasons&#xD;
             such as clinical laboratory abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hukeun Lee, MS</last_name>
    <phone>+82-2-6477-0208</phone>
    <email>hukeun.lee@kolmar.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seokuee Kim, MD, PhD</last_name>
    <phone>+82-2-6477-0207</phone>
    <email>seokuee.kim@kolmar.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital, Dept. of Clinical Pharmacology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <phone>82-2-2072-1666</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

